Trevor Williams Eton Pharmaceuticals ( NASDAQ: ETON ) to acquire Increlex from Ipsen S.A. ( OTCPK:IPSEY ).
Increlex is a biologic product used to treat children and adolescents from 2- to 18-years-old who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD) because their bodies do not make enough insulin-like.
